182 related articles for article (PubMed ID: 20974296)
1. The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis.
Fabris M; Quartuccio L; Lombardi S; Saracco M; Atzeni F; Carletto A; Cimmino M; Fabro C; Pontarini E; Pellerito R; Bambara LM; Sarzi-Puttini P; Cutolo M; Manfredi M; Benucci M; Morassi P; Fischetti F; Padovan M; Govoni M; Curcio F; Tonutti E; De Vita S
Autoimmun Rev; 2012 Mar; 11(5):315-20. PubMed ID: 20974296
[TBL] [Abstract][Full Text] [Related]
2. Study on the possible role of the -174G>C IL-6 promoter polymorphism in predicting response to rituximab in rheumatoid arthritis.
Fabris M; Quartuccio L; Lombardi S; Benucci M; Manfredi M; Saracco M; Atzeni F; Morassi P; Cimmino MA; Pontarini E; Fabro C; Pellerito R; Sarzi-Puttini P; Cutolo M; Carletto A; Bambara LM; Fischetti F; Curcio F; Tonutti E; De Vita S
Reumatismo; 2010; 62(4):253-8. PubMed ID: 21253618
[TBL] [Abstract][Full Text] [Related]
3. Association between -871C>T promoter polymorphism in the B-cell activating factor gene and the response to rituximab in rheumatoid arthritis patients.
Ruyssen-Witrand A; Rouanet S; Combe B; Dougados M; Le Loët X; Sibilia J; Tebib J; Mariette X; Constantin A
Rheumatology (Oxford); 2013 Apr; 52(4):636-41. PubMed ID: 23264555
[TBL] [Abstract][Full Text] [Related]
4. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
Quartuccio L; Fabris M; Salvin S; Atzeni F; Saracco M; Benucci M; Cimmino M; Morassi P; Masolini P; Pellerito R; Cutolo M; Puttini PS; De Vita S
Rheumatology (Oxford); 2009 Dec; 48(12):1557-9. PubMed ID: 19789202
[TBL] [Abstract][Full Text] [Related]
5. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Gabay C; van Riel PL; Nordström DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF
Ann Rheum Dis; 2011 Sep; 70(9):1575-80. PubMed ID: 21571731
[TBL] [Abstract][Full Text] [Related]
6. The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study.
Quartuccio L; Fabris M; Pontarini E; Salvin S; Zabotti A; Benucci M; Manfredi M; Biasi D; Ravagnani V; Atzeni F; Sarzi-Puttini P; Morassi P; Fischetti F; Tomietto P; Bazzichi L; Saracco M; Pellerito R; Cimmino M; Schiavon F; Carraro V; Semeraro A; Caporali R; Cavagna L; Bortolotti R; Paolazzi G; Govoni M; Bombardieri S; De Vita S
Ann Rheum Dis; 2014 Apr; 73(4):716-21. PubMed ID: 23505228
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register.
Soliman MM; Hyrich KL; Lunt M; Watson KD; Symmons DP; Ashcroft DM;
J Rheumatol; 2012 Feb; 39(2):240-6. PubMed ID: 22174201
[TBL] [Abstract][Full Text] [Related]
8. Predictive factors of rituximab response in rheumatoid arthritis: results from a French university hospital.
Couderc M; Mathieu S; Pereira B; Glace B; Soubrier M
Arthritis Care Res (Hoboken); 2013 Apr; 65(4):648-52. PubMed ID: 23045227
[TBL] [Abstract][Full Text] [Related]
9. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study.
Sellam J; Hendel-Chavez H; Rouanet S; Abbed K; Combe B; Le Loët X; Tebib J; Sibilia J; Taoufik Y; Dougados M; Mariette X
Arthritis Rheum; 2011 Apr; 63(4):933-8. PubMed ID: 21225699
[TBL] [Abstract][Full Text] [Related]
10. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
[TBL] [Abstract][Full Text] [Related]
11. Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis.
Sellam J; Rouanet S; Hendel-Chavez H; Abbed K; Sibilia J; Tebib J; Le Loët X; Combe B; Dougados M; Mariette X; Taoufik Y
Arthritis Rheum; 2011 Dec; 63(12):3692-701. PubMed ID: 22127692
[TBL] [Abstract][Full Text] [Related]
12. CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis.
Sellam J; Rouanet S; Hendel-Chavez H; Miceli-Richard C; Combe B; Sibilia J; Le Loët X; Tebib J; Jourdan R; Dougados M; Taoufik Y; Mariette X
Arthritis Rheum; 2013 Sep; 65(9):2253-61. PubMed ID: 23740460
[TBL] [Abstract][Full Text] [Related]
13. Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome.
Dávila-Fajardo CL; Márquez A; Pascual-Salcedo D; Moreno Ramos MJ; García-Portales R; Magro C; Alegre-Sancho JJ; Balsa A; Cabeza-Barrera J; Raya E; Martín J
Pharmacogenet Genomics; 2014 Jan; 24(1):1-5. PubMed ID: 24253594
[TBL] [Abstract][Full Text] [Related]
14. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment.
Lal P; Su Z; Holweg CT; Silverman GJ; Schwartzman S; Kelman A; Read S; Spaniolo G; Monroe JG; Behrens TW; Townsend MJ
Arthritis Rheum; 2011 Dec; 63(12):3681-91. PubMed ID: 22127691
[TBL] [Abstract][Full Text] [Related]
15. Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients.
Thurlings RM; Boumans M; Tekstra J; van Roon JA; Vos K; van Westing DM; van Baarsen LG; Bos C; Kirou KA; Gerlag DM; Crow MK; Bijlsma JW; Verweij CL; Tak PP
Arthritis Rheum; 2010 Dec; 62(12):3607-14. PubMed ID: 20722020
[TBL] [Abstract][Full Text] [Related]
16. Influence of gender on response to rituximab in patients with rheumatoid arthritis: results from the Autoimmunity and Rituximab registry.
Couderc M; Gottenberg JE; Mariette X; Pereira B; Bardin T; Cantagrel A; Combe B; Dougados M; Flipo RM; Le Loët X; Shaeverbeke T; Ravaud P; Soubrier M;
Rheumatology (Oxford); 2014 Oct; 53(10):1788-93. PubMed ID: 24821852
[TBL] [Abstract][Full Text] [Related]
17. [Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNFalpha agents failed are associated with response to rituximab in rheumatoid arthritis].
Quartuccio L; Salvin S; Saracco M; Lombardi S; Fabris M; Mansutti E; Maset M; Pellerito S; De Vita S
Reumatismo; 2009; 61(3):182-6. PubMed ID: 19888503
[TBL] [Abstract][Full Text] [Related]
18. [Optimizing rheumatoid arthritis treatment with rituximab--individualized patient approach].
Novak S
Reumatizam; 2010; 57(2):156-7. PubMed ID: 21875021
[TBL] [Abstract][Full Text] [Related]
19. Apoptotic effect of rituximab on peripheral blood B cells in rheumatoid arthritis.
Szodoray P; Alex P; Dandapani V; Nakken B; Pesina J; Kim X; Wallis GL; Wilson PC; Jonsson R; Centola M
Scand J Immunol; 2004; 60(1-2):209-18. PubMed ID: 15238091
[TBL] [Abstract][Full Text] [Related]
20. High anti-CCP antibody titres predict good response to rituximab in patients with active rheumatoid arthritis.
Gardette A; Ottaviani S; Tubach F; Roy C; Nicaise-Roland P; Palazzo E; Gill G; Meyer O; Dieudé P
Joint Bone Spine; 2014 Oct; 81(5):416-20. PubMed ID: 24998790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
